These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 3117843

  • 1. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.
    Jones RN, Barry AL.
    J Clin Microbiol; 1987 Oct; 25(10):1920-5. PubMed ID: 3117843
    [Abstract] [Full Text] [Related]

  • 2. Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.
    Barry AL, Jones RN.
    J Clin Microbiol; 1988 Apr; 26(4):750-4. PubMed ID: 3130390
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid.
    Fuchs PC, Barry AL, Jones RN.
    J Clin Microbiol; 1988 Jun; 26(6):1246-7. PubMed ID: 3384939
    [Abstract] [Full Text] [Related]

  • 4. Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks.
    Barry AL, Jones RN, Thornsberry C.
    J Clin Microbiol; 1984 Feb; 19(2):134-9. PubMed ID: 6321543
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: analysis of the correlations between in vitro test results and clinical response.
    Jones RN, Dudley MN.
    Diagn Microbiol Infect Dis; 1997 May; 28(1):5-18. PubMed ID: 9218913
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro activity of ampicillin, amoxicillin, ampicillin-sulbactam, and amoxicillin-clavulanic acid against consecutive clinical isolates of Enterobacteriaceae.
    Fuchs PC, Barry AL, Pfaller MA, Hardy DJ, McLaughlin JC, Gerlach EH.
    Diagn Microbiol Infect Dis; 1993 May; 17(2):171-5. PubMed ID: 8243040
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.
    Barry AL, Jones RN.
    J Clin Microbiol; 1988 Jan; 26(1):13-7. PubMed ID: 3343304
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
    Jones RN, Sutton LD, Cantrell HF, Lankford RB.
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):143-9. PubMed ID: 7874881
    [Abstract] [Full Text] [Related]

  • 18. Ampicillin-sulbactam susceptibility testing criteria.
    Barry A, Pfaller M, Fuchs P, Gerlach E, Hardy D, McLaughlin J.
    Eur J Clin Microbiol Infect Dis; 1993 Jun; 12(6):469-72. PubMed ID: 8359171
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.